| Literature DB >> 31277588 |
Tsegaye Alemayehu1, Mulubrahan Ali2, Enkosilassie Mitiku3, Mengistu Hailemariam3.
Abstract
BACKGROUND: Antibiotic resistance is a worldwide problem that crosses international boundaries and spread between continents easily. Hence, information on the existence of the causative microorganisms and their susceptibility to commonly used antibiotics are essential to enhance therapeutic outcome.Entities:
Keywords: Antibiotics resistance; Clinical samples; Southern Ethiopia
Mesh:
Substances:
Year: 2019 PMID: 31277588 PMCID: PMC6612117 DOI: 10.1186/s12879-019-4210-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Age and sex distribution of patients with bacterial isolates, HUCSH, Southern Ethiopia
| Age group in year | Sex | Total Bacteria (%) | |
|---|---|---|---|
| Male N (%) | Female N (%) | ||
| < 5 | 189(51.2) | 145(44.8) | 334(48.2) |
| 5–14 | 62(16.8) | 68(21) | 130(18.8) |
| 14–24 | 33(8.9) | 29(9) | 62(8.9) |
| 24–64 | 74(20.1) | 73(22.5) | 147(21.2) |
| > 64 | 11(3) | 9(2.8) | 20(2.9) |
| Total | 369(100) | 324(100) | 693(100) |
Distribution of sample type and bacterial isolates from a study of the burden of antimicrobial resistance at HUCSH, southern Ethiopia
| Specimen type | Total | |||||||||||
| Isolates | Urine | Body Fluids | Stool | Ear Swab | Eye swab | CSF | Blood | Sputum | Puss | Nasal swab | Genital swab | |
|
| 22(8.8) | 6(31.6) |
| 5(11.9) | 6(50) | 0 | 19(14.5) | 1(5.9) | 97(51.1) | 0 | 0 | 156(22.5) |
|
| 9(3.6) | 0 | 0 | 0 | 0 | 0 | 55(42) | 0 | 0 | 0 | 0 | 64(9.2) |
|
| 17(6.8) | 1(5.3) |
| 0 | 1(8.3) | 0 | 10(7.6) | 1(5.9) | 1(0.5) | 0 | 0 | 31(4.5) |
|
| 0 | 0 | 0 | 3(7.1) | 0 | 1(14.3) | 3(2.3) | 0 | 0 | 0 | 0 | 7(1) |
|
| 79(31.5) | 5 (26.3) | 0 | 9(21.4) | 2(16.7) | 0 | 26(19.8) | 8(47.1) | 25(13.2) | 0 | 0 | 154(22.2) |
|
| 70(27.9) | 2(10.5) | 0 | 9(21.4) | 1(8.3) | 2(28.6) | 5(3.8) | 0 | 26(13.7) | 1 (50) | 0 | 116(16.7) |
|
| 11(4.4) | 1(5.3) | 0 | 9(21.4) | 0 | 0 | 7(5.3) | 3(17.6) | 15(7.9) | 1 (50) | 0 | 47(6.8) |
|
| 16(6.4) | 3(15.8) | 0 | 2(4.8) | 1(8.3) | 0 | 1(0.8) | 2(11.8) | 7(3.7) | 0 | 0 | 32(4.6) |
|
| 16(6.4) | 0 | 0 | 0 | 1(8.3) | 0 | 2(1.5) | 1(5.9) | 4(2.1) | 0 | 0 | 24(3.5) |
|
| 4(1.6) | 0 | 0 | 1(2.4) | 0 | 0 | 2(1.5) | 1(5.9) | 10(5.3) | 0 | 0 | 18(2.6) |
|
| 6(2.4) | 1(5.3) | 0 | 4(9.5) | 0 | 0 | 0 | 0 | 5(2.6) | 0 | 0 | 16(2.3) |
|
| 0 | 0 | 12(63.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12(1.7) |
|
| 1(0.4) | 0 | 7(36.8) | 0 | 0 | 0 | 1(0.8) | 0 | 0 | 0 | 0 | 9(1.3) |
|
| 0 | 0 | 0 | 0 | 0 | 4(57.1) | 0 | 0 | 0 | 0 | 0 | 4(0.6) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3(100) | 3(0.4) |
|
| 251(36.2) | 19(2.7) | 19(2.7) | 42(6.1) | 12(1.7) | 7(1) | 131(18.9) | 17(2.5) | 190(27.4) | 2(0.3) | 3(0.4) | 693(100) |
Antibiotics resistance patterns of GPB, HUCSH, and Southern Ethiopia
| Antibiotics |
|
|
| Total | |
|---|---|---|---|---|---|
| R (%) | R (%) | R (%) | R (%) | R (%) | |
| AMP | NR | NR | 20(74.1) | NR | 20(74.1) |
| GEN | 42(31.8) | 32(55.2) | NR | NR | 74(38.9) |
| COT | 61(73.5) | 49(90.7) | NR | 4(66.7) | 116(81.1) |
| PEN | 41(80.4) | 24(92.3) | 6(75) | 1(33.3) | 72(81.8) |
| CAF | 22(19.5) | 22(40.7) | 8(34.8) | 3(60) | 55(28.2) |
| CLD | 2(5.3) | ND | NR | NR | 2(5.3) |
| NOR | 15(65.2) | 3(33.3) | 10(83.3) | NR | 28(63.6) |
| NIT | 1(14.3) | ND | 1(12.5) | NR | 2(13.3) |
| ERY | 20(31.7) | 9(50) | 11(73.3) | 0(0) | 40(40.4) |
| TAT | 11(61.1) | ND | 3(100) | 0(0) | 14(63.6) |
| CIP | 42(31.8) | 27(46.6) | 19(76) | NR | 88(40.9) |
| AUG | 51(52) | 24(39.3) | NR | NR | 75(47.2) |
| CTR | 39(45.3) | 22(41.5) | NR | NR | 61(43.9) |
| CAZ | 27(58.7) | 31(79.5) | NR | ND | 58(68.2) |
NR- Not recommended, ND-not done, R-Resistance, T- total tested, CoNS- coagulase-negative staphylococcus, ampicillin (AMP)(10 μg), gentamicin-Gen(10 μg), ciprofloxacin-CRP(5 μg), ceftriaxone-CRT(30 μg), ceftazidime-CAZ(30 μg), norfloxacin-NOR)(10 μg), nitrofurantoin-NIT(300 μg), augmentin-AUG(20/10 μg), cotrimoxazole-COT(1.25/23.75 μg), chloramphenicol-CAF(30 μg), meropenem-MER(10 μg), tetracycline-TAT(30 μg), penicillin G-PEN(10 IU), Clindamycin-CLD(2 μg) and erythromycin-ERY(15 μg).
Antibiotics resistance patterns of Enterobacteriaceae, HUCSH Southern Ethiopia
| Antibiotics |
|
| Total | |||||
|---|---|---|---|---|---|---|---|---|
| R (%) | R (%) | R (%) | R (%) | R (%) | R (%) | R (%) | R (%) | |
| AMP | 84(92.3) | 106(93.8) | 17(94.4) | 21(91.3) | 8(88.9) | 6(75) | 5(100) | 247(92.5) |
| GEN | 55(55.6) | 107(79.3) | 15(78.9) | 16(61.5) | 7(50) | 4(40) | 3(50) | 207(67) |
| CRP | 51(48.1) | 57(41.3) | 8(38.1) | 6(22.2) | 5(55.6) | 2(25) | 3(33.3) | 132(41.5) |
| CTR | 50(66.7) | 97(86.6) | 10(83.3) | 14(63.6) | 8(61.5) | 5(50) | 4(50) | 188(74.6) |
| CAZ | 28(56) | 46(78) | 4(66.7) | 3(37.5) | 2(40) | 2(100) | 1(100) | 86(65.6) |
| NOR | 46(61.3) | 35(43.8) | 8(47.1) | 6(31.6) | 4(66.7) | ND | – | 100(50.8) |
| NIT | 1(3.8) | 1(7.1) | 1(11.1) | 1(16.7) | 1(100) | ND | 0(0) | 5(8.7) |
| AUG | 65(65.7) | 93(74.4) | 14(82.4) | 15(60) | 5(38.5) | 4(50) | 4(57.1) | 200(68) |
| COT | 51(81) | 86(91.5) | 14(82.4) | 6(54.5) | 5(83.3) | 4(80) | 4(100) | 170(85) |
| CAF | 26(36.6) | 51(51) | 5(50) | 8(42.1) | 4(50) | 3(42.9) | 3(42.9) | 100(45.1) |
| MER | 0(0) | 3(13.6) | 5(62.5) | 2(42.9) | 0(0) | ND | 0(0) | 11(22.9) |
| TAT | 6(100) | 4(100) | 3(60) | 4(100) | 0(0) | ND | ND | 17(85) |
ND-Not done, R-Resistance, ampicillin (AMP)(10 μg), gentamicin-Gen(10 μg), ciprofloxacin-CRP(5 μg), ceftriaxone-CRT(30 μg), ceftazidime-CAZ(30 μg), norfloxacin-NOR)(10 μg), nitrofurantoin-NIT(300 μg), augmentin-AUG(20/10 μg), cotrimoxazole-COT(1.25/23.75 μg), chloramphenicol-CAF(30 μg), meropenem-MER(10 μg), tetracycline-TAT(30 μg)
Antibiotics resistance patterns of non- Enterobacteriaceae group at HUCSH, Southern Ethiopia
| Antibiotics | Total | ||||
|---|---|---|---|---|---|
| R (%) | R (%) | R (%) | R (%) | R (%) | |
| Amp | 23(92) | 15(88.2) | NR | ND | 39(92.9) |
| Gen | 22(55.2) | 11(84.6) | NR | ND | 33(62.2) |
| CRP | 14(32.6) | 9(56.2) | 2(100) | 2(50) | 27(41.5) |
| CTR | 23(67.6) | 10(76.9) | 2(66.7) | 1(100) | 38(71.7) |
| CAZ | 10(47.6) | 3(75) | 1(100) | 1(100) | 15(55.6) |
| NOR | 3(25) | 3(60) | NR | ND | 7(41.2) |
| AUG | 24(85.7) | 11(78.6) | NR | 1(100) | 36(83.7) |
| COT | 15(88.2) | 10(100) | NR | 1(50) | 27(93.1) |
| CAF | 14(70) | 10(83.3) | NR | 2(100) | 26(76.5) |
| MER | 2(50) | 2(50) | NR | ND | 4(50) |
| TAT | 3(100) | 2(100) | ND | NR | 5(100) |
ND-not done, NR-not recommended, ampicillin (AMP)(10 μg), gentamicin-Gen(10 μg), ciprofloxacin-CRP(5 μg), ceftriaxone-CRT(30 μg), ceftazidime-CAZ(30 μg), norfloxacin-NOR)(10 μg), nitrofurantoin-NIT(300 μg), augmentin-AUG(20/10 μg), cotrimoxazole-COT(1.25/23.75 μg), chloramphenicol-CAF(30 μg), meropenem-MER(10 μg), tetracycline-TAT(30 μg).
Fig. 1Multi-drug resistance in a study of the burden of antimicrobial resistance at HUCSH